vs

Side-by-side financial comparison of BICYCLE THERAPEUTICS PLC (BCYC) and WESTAMERICA BANCORPORATION (WABC). Click either name above to swap in a different company.

WESTAMERICA BANCORPORATION is the larger business by last-quarter revenue ($63.3M vs $48.0M, roughly 1.3× BICYCLE THERAPEUTICS PLC). WESTAMERICA BANCORPORATION runs the higher net margin — 43.9% vs -42.0%, a 85.9% gap on every dollar of revenue. On growth, BICYCLE THERAPEUTICS PLC posted the faster year-over-year revenue change (1193.3% vs -9.0%). WESTAMERICA BANCORPORATION produced more free cash flow last quarter ($119.7M vs $-19.9M). Over the past eight quarters, BICYCLE THERAPEUTICS PLC's revenue compounded faster (56.7% CAGR vs -8.6%).

Bicycle Therapeutics PLC is a clinical-stage biopharmaceutical firm developing innovative bicyclic peptide therapies for unmet medical needs. Its core pipeline covers oncology, rare diseases, and immunological disorders, with operations in Europe and North America, and partnerships with global pharma leaders to advance drug candidates to market.

Westamerica Bancorporation is a regional bank holding company headquartered in California, U.S. It operates via its wholly owned banking subsidiary to provide full-spectrum retail and commercial banking services, including deposit products, business and consumer loans, wealth management, and payment services, primarily serving individual consumers, SMEs and local institutional clients in northern and central California.

BCYC vs WABC — Head-to-Head

Bigger by revenue
WABC
WABC
1.3× larger
WABC
$63.3M
$48.0M
BCYC
Growing faster (revenue YoY)
BCYC
BCYC
+1202.3% gap
BCYC
1193.3%
-9.0%
WABC
Higher net margin
WABC
WABC
85.9% more per $
WABC
43.9%
-42.0%
BCYC
More free cash flow
WABC
WABC
$139.6M more FCF
WABC
$119.7M
$-19.9M
BCYC
Faster 2-yr revenue CAGR
BCYC
BCYC
Annualised
BCYC
56.7%
-8.6%
WABC

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
BCYC
BCYC
WABC
WABC
Revenue
$48.0M
$63.3M
Net Profit
$-20.2M
$27.8M
Gross Margin
Operating Margin
-51.5%
59.8%
Net Margin
-42.0%
43.9%
Revenue YoY
1193.3%
-9.0%
Net Profit YoY
61.1%
-12.3%
EPS (diluted)
$-0.29
$1.12

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
BCYC
BCYC
WABC
WABC
Q4 25
$48.0M
$63.3M
Q3 25
$11.7M
$63.7M
Q2 25
$2.9M
$64.6M
Q1 25
$10.0M
$66.4M
Q4 24
$3.7M
$69.6M
Q3 24
$2.7M
$74.1M
Q2 24
$9.4M
$74.3M
Q1 24
$19.5M
$75.8M
Net Profit
BCYC
BCYC
WABC
WABC
Q4 25
$-20.2M
$27.8M
Q3 25
$-59.1M
$28.3M
Q2 25
$-79.0M
$29.1M
Q1 25
$-60.8M
$31.0M
Q4 24
$31.7M
Q3 24
$-50.8M
$35.1M
Q2 24
$-39.8M
$35.5M
Q1 24
$-26.6M
$36.4M
Operating Margin
BCYC
BCYC
WABC
WABC
Q4 25
-51.5%
59.8%
Q3 25
-558.6%
59.5%
Q2 25
-2965.8%
60.5%
Q1 25
-703.7%
63.0%
Q4 24
62.8%
Q3 24
-2385.9%
64.5%
Q2 24
-498.3%
64.8%
Q1 24
-162.4%
65.2%
Net Margin
BCYC
BCYC
WABC
WABC
Q4 25
-42.0%
43.9%
Q3 25
-503.7%
44.3%
Q2 25
-2703.8%
45.0%
Q1 25
-608.9%
46.7%
Q4 24
45.6%
Q3 24
-1898.4%
47.3%
Q2 24
-425.3%
47.8%
Q1 24
-136.0%
48.0%
EPS (diluted)
BCYC
BCYC
WABC
WABC
Q4 25
$-0.29
$1.12
Q3 25
$-0.85
$1.12
Q2 25
$-1.14
$1.12
Q1 25
$-0.88
$1.16
Q4 24
$1.19
Q3 24
$-0.74
$1.31
Q2 24
$-0.77
$1.33
Q1 24
$-0.62
$1.37

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
BCYC
BCYC
WABC
WABC
Cash + ST InvestmentsLiquidity on hand
$628.1M
Total DebtLower is stronger
Stockholders' EquityBook value
$610.0M
$933.5M
Total Assets
$717.6M
$6.0B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
BCYC
BCYC
WABC
WABC
Q4 25
$628.1M
Q3 25
$648.3M
Q2 25
$721.5M
Q1 25
$793.0M
Q4 24
$879.5M
Q3 24
$890.9M
Q2 24
$961.4M
Q1 24
$457.0M
Total Debt
BCYC
BCYC
WABC
WABC
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
$30.9M
Q1 24
$30.8M
Stockholders' Equity
BCYC
BCYC
WABC
WABC
Q4 25
$610.0M
$933.5M
Q3 25
$618.5M
$931.6M
Q2 25
$668.9M
$921.8M
Q1 25
$740.3M
$923.1M
Q4 24
$793.1M
$890.0M
Q3 24
$831.0M
$909.0M
Q2 24
$873.8M
$815.6M
Q1 24
$356.0M
$791.7M
Total Assets
BCYC
BCYC
WABC
WABC
Q4 25
$717.6M
$6.0B
Q3 25
$764.0M
$5.9B
Q2 25
$832.2M
$5.8B
Q1 25
$883.9M
$6.0B
Q4 24
$956.9M
$6.1B
Q3 24
$996.7M
$6.2B
Q2 24
$1.1B
$6.3B
Q1 24
$547.1M
$6.5B
Debt / Equity
BCYC
BCYC
WABC
WABC
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
0.04×
Q1 24
0.09×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
BCYC
BCYC
WABC
WABC
Operating Cash FlowLast quarter
$-19.3M
$121.9M
Free Cash FlowOCF − Capex
$-19.9M
$119.7M
FCF MarginFCF / Revenue
-41.5%
189.0%
Capex IntensityCapex / Revenue
1.2%
3.5%
Cash ConversionOCF / Net Profit
4.38×
TTM Free Cash FlowTrailing 4 quarters
$-252.0M
$213.4M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
BCYC
BCYC
WABC
WABC
Q4 25
$-19.3M
$121.9M
Q3 25
$-71.2M
$29.4M
Q2 25
$-72.8M
$23.5M
Q1 25
$-86.4M
$42.4M
Q4 24
$-164.7M
$141.6M
Q3 24
$-39.8M
$40.6M
Q2 24
$-44.6M
$19.0M
Q1 24
$-70.9M
$52.2M
Free Cash Flow
BCYC
BCYC
WABC
WABC
Q4 25
$-19.9M
$119.7M
Q3 25
$-71.8M
$28.7M
Q2 25
$-73.3M
$22.8M
Q1 25
$-87.0M
$42.2M
Q4 24
$-166.0M
$139.8M
Q3 24
$-40.3M
$40.1M
Q2 24
$-45.0M
$18.6M
Q1 24
$-70.9M
$52.1M
FCF Margin
BCYC
BCYC
WABC
WABC
Q4 25
-41.5%
189.0%
Q3 25
-612.3%
45.1%
Q2 25
-2509.7%
35.3%
Q1 25
-871.7%
63.5%
Q4 24
-4475.7%
201.0%
Q3 24
-1504.7%
54.1%
Q2 24
-481.2%
25.0%
Q1 24
-362.9%
68.7%
Capex Intensity
BCYC
BCYC
WABC
WABC
Q4 25
1.2%
3.5%
Q3 25
5.7%
1.1%
Q2 25
17.1%
1.1%
Q1 25
6.1%
0.3%
Q4 24
33.3%
2.5%
Q3 24
16.3%
0.7%
Q2 24
4.5%
0.6%
Q1 24
0.1%
0.2%
Cash Conversion
BCYC
BCYC
WABC
WABC
Q4 25
4.38×
Q3 25
1.04×
Q2 25
0.81×
Q1 25
1.37×
Q4 24
4.47×
Q3 24
1.16×
Q2 24
0.54×
Q1 24
1.43×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons